Evaluation of a mobile phone-based, advanced symptom management system (ASyMS) in the management of chemotherapy-related toxicity

N Kearney, L McCann, J Norrie, L Taylor, P Gray, M McGee-Lennon, M Sage, M Miller, R Maguire, N Kearney, L McCann, J Norrie, L Taylor, P Gray, M McGee-Lennon, M Sage, M Miller, R Maguire

Abstract

Objectives: To evaluate the impact of a mobile phone-based, remote monitoring, advanced symptom management system (ASyMS) on the incidence, severity and distress of six chemotherapy-related symptoms (nausea, vomiting, fatigue, mucositis, hand-foot syndrome and diarrhoea) in patients with lung, breast or colorectal cancer.

Design: A two group (intervention and control) by five time points (baseline, pre-cycle 2, pre-cycle 3, pre-cycle 4 and pre-cycle 5) randomised controlled trial.

Setting: Seven clinical sites in the UK; five specialist cancer centres and two local district hospitals.

Participants: One hundred and twelve people with breast, lung or colorectal cancer receiving outpatient chemotherapy.

Interventions: A mobile phone-based, remote monitoring, advanced symptom management system (ASyMS).

Main outcome measures: Chemotherapy-related morbidity of six common chemotherapy-related symptoms (nausea, vomiting, fatigue, mucositis, hand-foot syndrome and diarrhoea).

Results: There were significantly higher reports of fatigue in the control group compared to the intervention group (odds ratio = 2.29, 95%CI = 1.04 to 5.05, P = 0.040) and reports of hand-foot syndrome were on average lower in the control group (odds ratio control/intervention = 0.39, 95%CI = 0.17 to 0.92, P = 0.031).

Conclusion: The study demonstrates that ASyMS can support the management of symptoms in patients with lung, breast and colorectal cancer receiving chemotherapy.

References

    1. Eur J Oncol Nurs. 2008 Sep;12(4):380-6
    1. CMAJ. 2001 Sep 18;165(6):765-71
    1. Eur J Heart Fail. 2003 Oct;5(5):583-90
    1. Cancer. 1986 Aug 1;58(3):796-800
    1. J Allergy Clin Immunol. 2005 Jun;115(6):1137-42
    1. Cancer. 2006 May 15;106(10):2258-66
    1. Cancer Pract. 2002 May-Jun;10(3):147-54
    1. J Pain Symptom Manage. 1995 Oct;10(7):510-20
    1. Chemotherapy. 2004 Oct;50(4):157-61
    1. Comput Methods Programs Biomed. 2002 Aug;69(2):137-46
    1. Oncol Nurs Forum. 1988 May-Jun;15(3):325-30
    1. Control Clin Trials. 2002 Dec;23(6):662-74
    1. J Clin Oncol. 2002 Dec 15;20(24):4636-42
    1. Int J Palliat Nurs. 2008 Sep;14(9):426-31
    1. Eur J Cancer Care (Engl). 2009 Mar;18(2):156-64
    1. Eur J Oncol Nurs. 2007 Jul;11(3):238-46
    1. Support Care Cancer. 2006 Jul;14(7):742-52
    1. Am J Health Syst Pharm. 2004 Apr 1;61(7):722-3
    1. Eval Health Prof. 2005 Dec;28(4):464-78
    1. Can J Gastroenterol. 2005 Feb;19(2):83-7
    1. Semin Hematol. 1997 Jul;34(3 Suppl 2):4-12
    1. Lancet. 2003 Aug 23;362(9384):640-50
    1. Soc Sci Med. 2003 Aug;57(4):697-710
    1. J Telemed Telecare. 2005;11 Suppl 1:43-6
    1. Int J Nurs Stud. 2001 Oct;38(5):497-510
    1. Cancer Causes Control. 2006 Jun;17(5):647-54
    1. Am J Manag Care. 2006 Aug;12(8):467-74

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe